Lupus is an autoimmune disease; there are two types of lupus, discoid lupus erythematosus and systemic lupus erythematosus. For today I will mainly discuss systemic lupus. Just like I explained in my previous column, an autoimmune disease is a response from an overactive immune system. The immune system mistakes healthy tissue in the body as a foreign invader, such as a bacteria or virus.
Discoid Lupus Erythematosus (DLE) is a chronic disease in which there is no cure. DLE causes inflamed red scaly or crusty lesions to appear on the skin. Primarily favoring the face, ears, and scalp, but they can show up on any part of the body. These lesions can leave behind permanent scarring especially when they appear in areas where hair grows like the scalp or face.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.